Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
October 11, 2023 12:00 ET
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
October 04, 2023 16:05 ET
|
Revolution Medicines, Inc.
Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m....
DNA Extraction, Isolation, Purification Market Worth $6.10 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
October 04, 2023 09:25 ET
|
The Insight Partners
Pune, India, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The method through which the DNA is purified is DNA extraction, by using physical and/or chemical methods from proteins, cell membranes, and other...
Projected Market Value: mTOR Inhibitors Market Set to Reach $8.76 Billion by 2027 with Novartis and Pfizer in the Lead
September 20, 2023 04:38 ET
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "mTOR Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global mTOR inhibitors market is on a...
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
September 19, 2023 07:00 ET
|
Revolution Medicines, Inc.
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers ...
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 17, 2023 16:05 ET
|
Revolution Medicines, Inc.
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE...
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 08, 2023 16:05 ET
|
Revolution Medicines, Inc.
Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple...
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 03, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Upcoming Investor Conferences
June 08, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Global KRAS Inhibitors Market Research Report 2023: A $4 Billion Opportunity by 2029, 200% Growth in 2022, 60 Drugs in Clinical Trials, 2 Approved Drugs
June 07, 2023 10:18 ET
|
Research and Markets
Dublin, June 07, 2023 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. ...